Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Cantor Fitzgerald Maintains Overweight on Pliant Therapeutics, Raises Price Target to $40

Cantor Fitzgerald Maintains Overweight on Pliant Therapeutics, Raises Price Target to $40

Cantor Fitzgerald analyst Pete Stravropoulos maintains Pliant Therapeutics (NASDAQ:PLRX) with a Overweight and raises the price target from $36 to $40.

byBenzinga Newsdesk

July 26, 2022

1 minute read

Cantor Fitzgerald analyst Pete Stravropoulos maintains Pliant Therapeutics (NASDAQ:PLRX) with a Overweight and raises the price target from $36 to $40.

Analyst Ratings

The Analyst Landscape: 5 Takes On Northern Trust

By Benzinga Insights

April 4, 4:00 PM

Providing a diverse range of perspectives from bullish to bearish, 5 analysts have published ratings on Northern Trust…

NTRS

Specialty Products Maker Brady Increases Annual Dividend By 2%

By Shivani Kumaresan

September 5, 6:47 AM

Brady Corp (NYSE: BRC) said its Board of Directors approved an increase in the annual dividend to shareholders from $0.92 per share to $0.94 per share, representing a 2.2% increase.

BRC